Ads
related to: monoclonal antibody treatment prostate cancer debate video today full episode- Sign Up For Updates
Rx For Advanced Prostate Cancer
Get Information & Updates
- Coverage for Rx Treatment
Learn About Coverage
In Your Area
- Formulary Lookup Tool
View our Formulary Lookup
For a Prostate Cancer Treatment
- Patient Support Program
Support to Help Your Patients
Get Started and Stay on Track
- Sign Up For Updates
Search results
Results from the WOW.Com Content Network
Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide , a derivative of DTPA . [ 2 ] Pendetide acts as a chelating agent for the radionuclide indium-111 .
It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin.The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.
Anti-cancer monoclonal antibodies can be targeted against malignant cells by several mechanisms. Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies. [18] In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy. [19]
Ipilimumab, in combination with nivolumab, is indicated for the treatment of adults and adolescents twelve years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Durvalumab, [8] sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer. [6] It was developed by Medimmune / AstraZeneca . [ 9 ] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ).
Ponsegromab (PF-06946860) is a monoclonal antibody that works as a GDF-15 inhibitor. It is developed by Pfizer for cancer cachexia. [1] [2] [3] [4] [5]In September ...
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. [1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators. This drug was developed by MacroGenics, Inc.
Ads
related to: monoclonal antibody treatment prostate cancer debate video today full episode